XtalPi
晶 泰 科 技

XtalPi Holdings Limited
晶泰控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2228)

VOLUNTARY ANNOUNCEMENT

VOLUNTARY FURTHER EXTENSION OF LOCK-UP UNDERTAKINGS BY THE CO-FOUNDERS

This announcement is made by XtalPi Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

Reference is made to the announcement of the Company dated 26 May 2025 in relation to, among others, the voluntary extension of the expiry date of the lock-up undertaking in relation to the shares of the Company beneficially held by Dr. Wen Shuhao, Dr. Ma Jian and Dr. Lai Lipeng (the "**Founders**"), each a co-founder and executive director of the Company, from 12 June 2025 to 12 June 2026.

The Company has been informed that the Founders, as a demonstration of confidence in the long term value of the Company, have voluntarily further extended the expiry date of their lock-up undertakings to not dispose of certain shares of the Company in which each of them is beneficially interested (the "**Relevant Shares**") for a further 12 months, from 12 June 2026 (the original expiry date) to 12 June 2027 (the new expiry date).

The total number of the Relevant Shares is 555,171,595 shares, representing approximately 12.9% of the issued share capital of the Company as at the date of this announcement, comprising shares of the Company held by companies controlled by the relevant Founder and shares of the Company held by QuantumPharm Roc Holdings Limited ("**QuantumPharm Roc**"), which represent the underlying the outstanding options held by the relevant Founder and which will be transferred by QuantumPharm Roc to the relevant Founder upon his exercise of the options.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares and other securities of the Company.

By Order of the Board
XtalPi Holdings Limited
Dr. Wen Shuhao
Chairman of the Board and Executive Director

Hong Kong, 25 May 2026

As at the date of this announcement, the Board comprises Dr. Wen Shuhao, Dr. Ma Jian, Dr. Lai Lipeng and Dr. Jiang Yide Alan as executive Directors, and Mr. Law Cheuk Kin Stephen, Ms. Chan Wing Ki and Mr. Chow Ming Sang as independent non-executive Directors.